View Older Stories View More Recent Stories

Feb 18, 2021 08:00AM Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 12, 2021 02:16PM Astellas and Seagen (SGEN) Announce Presentation of Results from PADCEV Pivotal Trial in Patients with Previously Treated Advanced UC Who Were Ineligible for Cisplatin Chemotherapy
Feb 12, 2021 02:15PM Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Feb 12, 2021 02:15PM Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Feb 12, 2021 02:15PM Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Feb 12, 2021 02:15PM Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Jan 28, 2021 01:28PM Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
Oct 12, 2020 06:46AM Seagen (SGEN) and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV in Advanced UC
Oct 12, 2020 06:45AM Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Oct 12, 2020 06:45AM Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Sep 18, 2020 06:45AM Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
Sep 18, 2020 06:45AM Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
May 27, 2020 02:30PM FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients
Mar 24, 2020 09:06AM CytomX Therapeutics (CTMX), Astellas Enter Collaboration to Develop Probody T-Cell
Mar 23, 2020 08:00PM CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer
Feb 19, 2020 08:28AM Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Feb 19, 2020 08:12AM Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Feb 11, 2020 08:00AM Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
Feb 10, 2020 05:02PM Seattle Genetics (SGEN) and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV for Advanced Bladder Cancer
Feb 10, 2020 05:00PM Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
Dec 19, 2019 06:27AM FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' (SGEN) PADCEV for People with Locally Advanced or Metastatic Urothelial Cancer
Dec 18, 2019 07:49PM FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder
Dec 18, 2019 06:36PM FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bla
Dec 2, 2019 08:04AM Seattle Genetics (SGEN), Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA in Patients with Metastatic Urothelial Cancer
Dec 2, 2019 08:00AM Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
Dec 2, 2019 08:00AM Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
Sep 28, 2019 02:30AM Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
Sep 28, 2019 02:30AM Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
Sep 16, 2019 08:00AM Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Sep 16, 2019 08:00AM Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 08:04AM Seattle Genetics (SGEN), Astellas Announce Submission of BLA to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 08:00AM Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 08:00AM Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 10, 2019 09:00AM Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales
Jun 3, 2019 07:32AM Seattle Genetics (SGEN), Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Canc
Jun 3, 2019 07:30AM Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
Jun 3, 2019 07:30AM Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
Mar 28, 2019 03:01AM Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 28, 2019 03:01AM Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Aug 21, 2018 08:05AM Ironwood Pharma (IRWD), Astellas Pharma Inc. Announce Japanese Approval of Linzess Tablets 0.25 mg for Additional Indication of Chronic Constipation
Aug 21, 2018 08:00AM Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
Jul 9, 2018 08:03AM Seattle Genetics (SGEN), Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 9, 2018 08:00AM Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 9, 2018 08:00AM Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jun 3, 2018 09:00AM Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Jun 3, 2018 09:00AM Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Mar 26, 2018 08:00AM Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 26, 2018 08:00AM Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Nov 8, 2017 08:00AM Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Nov 8, 2017 08:00AM Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
View More Recent Stories View Older Stories